Therapeutic strategies to address monkeypox.

Abstract

INTRODUCTION:

Monkeypox is a viral zoonosis, with symptoms similar to those seen in smallpox patients, although the clinical presentation may be less severe. Until recently, human monkeypox infection was rare, and primarily occurred in Central and West Africa.

AREAS COVERED:

An international outbreak began in May 2022, and monkeypox has now been detected on every continent except Antarctica. The first recognized case from the current outbreak was confirmed in the United Kingdom on 6 May 2022, in an adult with travel links to Nigeria, but it has been suggested that cases had been spreading in Europe for months. On 23 July 2022 the Director-General of the World Health Organization declared the monkeypox outbreak a public health emergency of international concern.

EXPERT OPINION:

There are no treatments specifically for monkeypox virus infections. However, monkeypox and smallpox viruses are genetically similar, and therapeutics developed to combat smallpox may be used to treat monkeypox. This manuscripts reviews what is known about these potential treatments, including tecovirimat and brincidofovir, based on a literature search of PubMed through 9 August 2022, and explores how these therapeutics may be used in the future to address the expanding monkeypox pandemic.

• Authors: Matthew W McCarthy
• Journal: Expert review of anti-infective therapy (Expert Rev Anti Infect Ther) Vol. 20 Issue 10 Pg. 1249-1252 (10 2022) ISSN: 1744-8336 [Electronic] England
• PMID: 35953443 (Publication Type: Journal Article)

Topics

• Adult
• Disease Outbreaks
• Humans
• Monkeypox (diagnosis, drug therapy, epidemiology)
• Monkeypox virus
• Public Health
• Smallpox (drug therapy, epidemiology)